Alemtuzumab

Shares in Bayer rose 2.1% in Germany after the pharmaceuticals company said multiple-sclerosis drug Alemtuzumab could be a blockbuster.

U.S. stocks trade lower 2008

Alemtuzumab appears to stop progression of the disease in patients with early stage active relapsing-remitting MS -- the most common form of the condition.

Markets, Governments Go 2008

Alemtuzumab is a humanized monoclonal antibody being studied as a potential therapy for relapsing MS. Alemtuzumab targets the cell-surface glycoprotein CD52, which is highly expressed on T- and B-lymphocytes.

unknown title 2011

Alemtuzumab appears to have little or no effect on other cells of the immune system.

unknown title 2011

Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis

Naturejobs - All Jobs Matthew P. Strout 2010

Alemtuzumab, they said, is more effective, convenient, and easier for patients to tolerate than treatments now on the market.

Boston.com Top Stories 2010

Alemtuzumab therapy depletes T cells and B cells which mistakenly attack healthy nerve structures but can leave patients at risk of infection and other adverse events.

Social Security Reports, News and Informaion MedPageToday.com - medical news plus CME for physi 2010

"Alemtuzumab for MS is probably the largest single program we've ever undertaken," Termeer said today at a meeting with shareholders in New York.

Sanofi Target Genzyme’s CEO Touts Campath MS Promise - Bloomberg 2010

Alemtuzumab therapy depletes T cells and B cells which mistakenly attack healthy nerve structures but can leave patients at risk of infection and other adverse events.

Social Security Reports, News and Informaion MedPageToday.com - medical news plus CME for physi 2010

Alemtuzumab is one year away from opening up the first Phase 3 clinical trial that we hope will confirm the tremendous results that we have seen in the Phase 2.

SeekingAlpha.com: Home Page 2010